Brokerages predict that Collegium Pharmaceutical, Inc. (NASDAQ:COLL) will post sales of $4.07 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Collegium Pharmaceutical’s earnings, with the highest sales estimate coming in at $4.84 million and the lowest estimate coming in at $3.62 million. The company is expected to issue its next earnings results after the market closes on Wednesday, August 9th.

On average, analysts expect that Collegium Pharmaceutical will report full-year sales of $4.07 million for the current year, with estimates ranging from $17.80 million to $30.08 million. For the next financial year, analysts anticipate that the business will report sales of $65.11 million per share, with estimates ranging from $45.64 million to $87.67 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Collegium Pharmaceutical.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Wednesday, May 10th. The specialty pharmaceutical company reported ($0.79) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.98) by $0.19. The company had revenue of $2.17 million for the quarter, compared to analyst estimates of $3.55 million.

A number of brokerages have weighed in on COLL. BidaskClub downgraded Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Friday. Zacks Investment Research downgraded Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Janney Montgomery Scott reissued a “buy” rating and set a $25.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, June 12th. Jefferies Group LLC reissued a “buy” rating and set a $22.00 price target (down previously from $24.00) on shares of Collegium Pharmaceutical in a research report on Thursday, May 11th. Finally, Needham & Company LLC lowered their price target on Collegium Pharmaceutical from $28.00 to $25.00 and set a “buy” rating on the stock in a research report on Thursday, May 11th. Three equities research analysts have rated the stock with a sell rating and five have issued a buy rating to the company. Collegium Pharmaceutical currently has a consensus rating of “Hold” and an average target price of $21.33.

Collegium Pharmaceutical (NASDAQ:COLL) opened at 11.32 on Friday. The stock’s 50 day moving average price is $12.18 and its 200-day moving average price is $12.12. The firm’s market cap is $333.46 million. Collegium Pharmaceutical has a one year low of $7.37 and a one year high of $20.55.

In other Collegium Pharmaceutical news, insider Paul Brannelly purchased 10,000 shares of the stock in a transaction on Friday, May 12th. The shares were purchased at an average price of $9.18 per share, with a total value of $91,800.00. Following the completion of the transaction, the insider now directly owns 110,227 shares in the company, valued at $1,011,883.86. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 25.76% of the stock is owned by insiders.

Institutional investors have recently made changes to their positions in the company. NBW Capital LLC increased its position in shares of Collegium Pharmaceutical by 1.8% in the first quarter. NBW Capital LLC now owns 62,030 shares of the specialty pharmaceutical company’s stock worth $624,000 after buying an additional 1,114 shares during the period. Credit Suisse AG increased its position in Collegium Pharmaceutical by 9.4% in the first quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock valued at $137,000 after buying an additional 1,173 shares during the last quarter. Nationwide Fund Advisors increased its position in Collegium Pharmaceutical by 16.4% in the first quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock valued at $101,000 after buying an additional 1,422 shares during the last quarter. American International Group Inc. increased its position in Collegium Pharmaceutical by 27.8% in the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock valued at $100,000 after buying an additional 2,163 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in Collegium Pharmaceutical by 6.1% in the first quarter. Bank of New York Mellon Corp now owns 65,305 shares of the specialty pharmaceutical company’s stock valued at $656,000 after buying an additional 3,775 shares during the last quarter. 82.36% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Collegium Pharmaceutical, Inc. (COLL) Expected to Announce Quarterly Sales of $4.07 Million” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/08/05/collegium-pharmaceutical-inc-coll-expected-to-announce-quarterly-sales-of-4-07-million.html.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.